Phase II Study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Patients with Newly Diagnosed AML at High Risk for Induction Mortality
The goal of this clinical research study is to compare different dose levels of CPX-351. The safety and efficacy of the drug will be studied in all dose levels.
Treatment Location: N/A
IRB Review and Approval Date: 05/04/2015
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: